FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial.

Clin Cancer Res · 2025 · PMC12402780 · PMID 40569606

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

In the secondary analysis focusing on DFS, a clear trend emerged: Patients classified as non-BLBC by VFOXC1 expression exhibited superior capecitabine efficacy compared with those classified as BLBC (Supplementary Fig.

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.